New Podcast with Back Bay and Nasdaq: Preparing Biopharma and Medtech Companies for Public Listing
In our latest industry podcast, Back Bay and Nasdaq share advice for preparing for public listing.
For biopharma and medtech companies, the commitment to go public is predicated on many business decisions—what kind of capital can be raised? Is our investor base strong and interested? Is now the right time? The Nordic Markets offer some distinct advantages at the earlier stage, and also offer new possibilities for US companies to list abroad.
In this episode of The Life Science Report, Back Bay Life Science Advisors and Nasdaq outline best practices for companies considering a public listing, including:
Steps in best practice strategy, in an increasingly complex market
Advantages of listing with a smaller listing threshold market
Similarities and differences between Nasdaq US and Nasdaq Nordic markets
The strategic change and new dual listing option for US companies
Differences in support for emerging companies, Nordic v. US markets
Preparing to go public? Download our tip sheet: Preparing for a Public Listing: Best Practices for Biopharma, Medtech and Healthtech Companies from Back Bay Life Science Advisors and Nasdaq.
Jonathan Gertler is CEO of Back Bay Life Science Advisors and Managing Partner at Bioventures Medtech Funds. Maria Groschopp Dellwik is Nasdaq’s Head of Strategy and Business Development for Global Listing Services in the Nordics, where she manages new offerings and key strategic change initiatives to improve listing offerings and the Swedish capital market.
View the video podcast here, or listen on your favorite podcast platform.